Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2013 Aug 16

PMID 23945604

Citations 194

Authors

Hm Jones

K Rowland-Yeo

Affiliations

Soon will be listed here.

Citing Articles

Bayesian inference informed by parameter subset selection for a minimal PBPK brain model.

Dadashova K, Smith R, Haider M, Reich B Philos Trans A Math Phys Eng Sci. 2025; 383(2292):20240219.

PMID: 40078152 PMC: 11904618. DOI: 10.1098/rsta.2024.0219.

Mass spectrometry methods and mathematical PK/PD model for decision tree-guided covalent drug development.

Hossain M, Brahme R, Miller B, Amin J, de Barros M, Schneider J Nat Commun. 2025; 16(1):1777.

PMID: 39971904 PMC: 11839910. DOI: 10.1038/s41467-025-56985-6.

Postpartum changes in maternal physiology and milk composition: a comprehensive database for developing lactation physiologically-based pharmacokinetic models.

Deferm N, Dinh J, Pansari A, Jamei M, Abduljalil K Front Pharmacol. 2025; 16:1517069.

PMID: 39963246 PMC: 11830814. DOI: 10.3389/fphar.2025.1517069.

Pharmacokinetics of 7,8-dihydroxyflavone in neonatal mice with hypoxia-ischemia related brain injury.

Lim S, Scarlett C, Yapici S, Ferrazzano P, Cengiz P Front Pharmacol. 2025; 15:1508696.

PMID: 39881861 PMC: 11775835. DOI: 10.3389/fphar.2024.1508696.

Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.

Zbib F, Deschamps A, Velly L, Blin O, Guilhaumou R, Gattacceca F Clin Pharmacokinet. 2025; 64(2):257-273.

PMID: 39762592 DOI: 10.1007/s40262-024-01469-x.

References

Schmitt W . General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2007; 22(2):457-67. DOI: 10.1016/j.tiv.2007.09.010. View

Tanaka C, Kawai R, Rowland M . Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos. 2000; 28(5):582-9. View

Nestorov I, Aarons L, Arundel P, Rowland M . Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm. 1998; 26(1):21-46. DOI: 10.1023/a:1023272707390. View

Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A . The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009; 5(2):211-23. DOI: 10.1517/17425250802691074. View

Agoram B, Woltosz W, Bolger M . Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001; 50 Suppl 1:S41-67. DOI: 10.1016/s0169-409x(01)00179-x. View

Parrott N, Lukacova V, Fraczkiewicz G, Bolger M . Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. AAPS J. 2009; 11(1):45-53. PMC: 2664880. DOI: 10.1208/s12248-008-9079-7. View

Niemi M, Kajosaari L, Neuvonen M, Backman J, Neuvonen P . The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol. 2004; 57(4):441-7. PMC: 1884466. DOI: 10.1046/j.1365-2125.2003.02027.x. View

Kajosaari L, Laitila J, Neuvonen P, Backman J . Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005; 97(4):249-56. DOI: 10.1111/j.1742-7843.2005.pto_157.x. View

Peyret T, Poulin P, Krishnan K . A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol. 2010; 249(3):197-207. DOI: 10.1016/j.taap.2010.09.010. View

10.

Shah D, Betts A . Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2011; 39(1):67-86. DOI: 10.1007/s10928-011-9232-2. View

11.

Nestorov I . Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2007; 3(2):235-49. DOI: 10.1517/17425255.3.2.235. View

12.

Johnson T, Boussery K, Rowland-Yeo K, Tucker G, Rostami-Hodjegan A . A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010; 49(3):189-206. DOI: 10.2165/11318160-000000000-00000. View

13.

Johnson T, Rostami-Hodjegan A, Tucker G . Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006; 45(9):931-56. DOI: 10.2165/00003088-200645090-00005. View

14.

Gertz M, Harrison A, Houston J, Galetin A . Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010; 38(7):1147-58. DOI: 10.1124/dmd.110.032649. View

15.

Poulin P, Theil F . Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci. 2009; 98(12):4941-61. DOI: 10.1002/jps.21759. View

16.

Mandic Z, Gabelica V . Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal. 2006; 41(3):866-71. DOI: 10.1016/j.jpba.2006.01.056. View

17.

Rostami-Hodjegan A . Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012; 92(1):50-61. DOI: 10.1038/clpt.2012.65. View

18.

Vicini P, van der Graaf P . Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?. Clin Pharmacol Ther. 2013; 93(5):379-81. DOI: 10.1038/clpt.2013.40. View

19.

Chen Y, Jin J, Mukadam S, Malhi V, Kenny J . Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos. 2012; 33(2):85-98. DOI: 10.1002/bdd.1769. View

20.

Fenneteau F, Poulin P, Nekka F . Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci. 2009; 99(1):486-514. DOI: 10.1002/jps.21802. View